Cost‐minimization study comparing Simulect^® vs. Thymoglobulin^® in renal transplant induction

Abstract

This study showed direct medical cost savings of 1159 Euros per patient in the Simulect arm, which more than compensated for the higher price of this immunosuppressive drug.